Corpseed

Ministry of Chemicals and Fertilizers Revises Drug Prices for 2026 under DPCO

Department: Department of PharmaceuticalsAuthority: Ministry of Chemicals and FertilizersPublish: Applicable: 01-04-2026Product Quality ComplianceMedical Device and Pharmaceutical

Quick note

Below is the official summary and the reference document preview. Use “Open PDF” for full screen view.

Schedule a Call Back

IN +91

Businesses we've worked with on drug licence

Clients include Cure and Care Wellness, 1008 Digital Health, Nfilade Security Solutions, Evoq Technologies, Kantika Import Export and Trading, Rock Well Industries, Abhay Healthtech, Hind Svasthya Healthcare, Pridus Global Pharma, Arka Brenstech, Believe Cosmetics, Imedicndr Healthcare (12 of 40+ served since 2018).

A few more clients we've served in this industry
Clients include
Cure and Care Wellness · 1008 Digital Health · Nfilade Security Solutions · Evoq Technologies · Kantika Import Export and Trading · Rock Well Industries · Abhay Healthtech · Hind Svasthya Healthcare · Pridus Global Pharma · Arka Brenstech · Believe Cosmetics · Imedicndr Healthcare · Katre Enterprises · Soapsquare Healthcare · Xsourcee
See our drug licence service →

Summary

The Ministry of Chemicals and Fertilizers has notified revised ceiling prices for scheduled formulations under the Drugs (Prices Control) Order (DPCO), 2013, based on an annual Wholesale Price Index (WPI) increase of 0.64956% for 2025 over 2024. The revised prices will be effective from 01 April 2026 and apply to key medicines, including Acetyl Salicylic Acid, Calcium Carbonate, Dapsone, Rifampicin, Medroxy Progesterone Acetate, and condoms.

Manufacturers selling above the notified ceiling price must reduce the Maximum Retail Price (MRP) in line with the revised limits, while those below may revise prices as per WPI provisions under Para 16(2). GST can be added only if actually payable. Manufacturers must submit price revisions in Form II within 15 days and issue updated price lists in Form V.

Retailers are required to display price lists prominently. Quarterly reporting in Form-III and prior intimation for discontinuation in Form-IV are mandatory. Non-compliance with ceiling price provisions will lead to recovery of overcharged amounts with interest under DPCO, 2013, and the Essential Commodities Act, 1955.

Document Preview

Embedded reference document

Fullscreen ↗

Related

Explore more updates from the same department.

Call